Technical Analysis for GBT - Global Blood Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 56.51 1.53% 0.85
GBT closed up 1.53 percent on Wednesday, July 17, 2019, on 52 percent of normal volume.

Earnings due: Aug 1

*** please verify all earnings dates ***
3 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical GBT trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Inside Day Range Contraction 0.00%
Bearish Engulfing Bearish 1.53%
Fell Below 20 DMA Bearish 1.53%
Fell Below 50 DMA Bearish 1.53%
Expansion Pivot Sell Setup Bearish Swing Setup 1.53%
Crossed Above 50 DMA Bullish -2.42%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.95%
Crossed Above 20 DMA Bullish -0.95%
MACD Bullish Signal Line Cross Bullish -0.95%

Older signals for GBT ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:
Profile
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in double-blind Phase I/II clinical trial indicated for the treatment of sickle cell disease. The company also focuses on developing an oral prophylactic therapy for hypoxemic pulmonary disorders and hereditary angioedema. The company was founded in 2011 and is based in South San Francisco, California.
Medicine Biopharmaceutical Medical Specialties Blood Hereditary Angioedema Sickle Cell Disease Angioedema Hemoglobin
Is GBT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jul 16 Should You Pick Up Novartis (NVS) Before Q2 Earnings?
Jul 16 Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA
Jul 10 GBT and Advocates Launch Disease Awareness Campaign Focused on Breaking Down Stigmas Associated with Sickle Cell Disease
Jul 9 Global Blood Therapeutics: My 3 Reasons For A Buy
Jul 6 Global Blood Therapeutics: Raining In The Desert With Voxelotor
Jul 5 Local researcher part of 'exciting' sickle cell drug trial
Jul 3 Global Blood Therapeutics: Voxelotor Can Take The Stock Price To New All-Time Highs
Jun 26 Why BlackBerry, AeroVironment, and Global Blood Therapeutics Slumped on Wednesday
Jun 26 INO, XSPA, EROS and GBT among midday movers
Jun 26 Inovio Pharmaceuticals and Neos Therapeutics among healthcare gainers; Mesoblast and OncoCyte among losers
See more GBT news...
Indicators
Indicator Value
52 Week High 64.94
52 Week Low 30.15
Average Volume 1,028,519
200-Day Moving Average 48.4296
50-Day Moving Average 57.5956
20-Day Moving Average 56.831
10-Day Moving Average 55.979
Average True Range 2.4103
ADX 15.91
+DI 20.7286
-DI 27.7287
Chandelier Exit (Long, 3 ATRs ) 57.7091
Chandelier Exit (Short, 3 ATRs ) 58.7909
Upper Bollinger Band 62.8401
Lower Bollinger Band 50.8219
Percent B (%b) 0.47
BandWidth 21.147261
MACD Line -0.3371
MACD Signal Line -0.4857
MACD Histogram 0.1486
Fundamentals Value
Market Cap 2.47 Billion
Num Shares 43.7 Million
EPS -2.46
Price-to-Earnings (P/E) Ratio -22.97
Price-to-Sales 0.00
Price-to-Book 5.19
PEG Ratio -0.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 59.48
Resistance 3 (R3) 59.40 58.32 58.99
Resistance 2 (R2) 58.32 57.57 58.37 58.82
Resistance 1 (R1) 57.42 57.10 57.87 57.50 58.65
Pivot Point 56.34 56.34 56.57 56.39 56.34
Support 1 (S1) 55.44 55.59 55.89 55.52 54.37
Support 2 (S2) 54.36 55.12 54.41 54.20
Support 3 (S3) 53.46 54.36 54.04
Support 4 (S4) 53.54